secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immix Biopharma, Inc. (IMMX)
CIK:        0001873835
Form:       8-K
Filed at:   2022-12-14T23:59:59+00:00
Accession:  0001493152-22-035437
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immix Biopharma in-licenses NXC-201 CAR-T with 71% complete response in multiple myeloma
--------------------------------------------------------------------------------

- In-licensed exclusive worldwide rights (ex-Israel/Middle East) to NXC-201 (BCMA-targeted CAR-T) from Hadasit and BIRAD.
- NXC-201 showed 85% ORR and 71% CR/sCR in 20 relapsed/refractory multiple myeloma patients; 100% ORR and organ response in AL amyloidosis.
- Zero neurotoxicity observed; median CRS duration of 2 days at therapeutic dose, supporting potential outpatient use.
- Financial terms: $1.5M upfront, $50k annual fee, mid-single digit royalties, up to $20M sales milestones.
- Formed wholly-owned subsidiary Nexcella to develop NXC-201; expects minimal impact on Immix financials as Nexcella independently financed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1873835/000149315222035437/0001493152-22-035437-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1873835/000149315222035437/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-035437

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer